Effects of liraglutide on weight loss, fat distribution, and b-cell function in obese subjects with prediabetes or early type 2 diabetes
| Autor: | Agostino Consoli, Marika Leo, Riccardo C. Bonadonna, Stefano Cianfarani, Augusto Di Castelnuovo, Lamberto Manzoli, Marica Tina Maccarone, Virginia Federico, Ermanno Angelucci, Giovanni Davì, Maria Teresa Guagnano, Paola Simeone, Cristina Sborgia, Armando Tartaro, Francesca Santilli |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Blood Glucose
Male Glycated Hemoglobin A Endocrinology Diabetes and Metabolism Adipose tissue Type 2 diabetes 030204 cardiovascular system & hematology Body Mass Index 0302 clinical medicine Weight loss Glucagon-Like Peptide 1 Risk Factors Insulin-Secreting Cells Adipocytes Prediabetes Longitudinal Studies Insulin-Like Growth Factor I Glucose tolerance test medicine.diagnostic_test adult Middle Aged Settore MED/38 Metformin Female liraglutide weight loss body fat distribution b-cell function obesity medicine.symptom Type 2 medicine.drug medicine.medical_specialty Diabetes Mellitus Type 2 Glucose Tolerance Test Humans Hypoglycemic Agents Insulin-Like Growth Factor II Life Style Liraglutide Lost to Follow-Up Obesity Prediabetic State Weight Loss Socio-culturale 030209 endocrinology & metabolism 03 medical and health sciences Internal medicine Diabetes mellitus Internal Medicine medicine Diabetes Mellitus Glycemic Glycated Hemoglobin Advanced and Specialized Nursing business.industry medicine.disease Endocrinology business |
| Popis: | OBJECTIVE Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. The risk depends significantly on adipose tissue distribution. Liraglutide, a glucagon-like peptide 1 analog, is associated with weight loss, improved glycemic control, and reduced cardiovascular risk. We determined whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese subjects with prediabetes or early type 2 diabetes. RESEARCH DESIGN AND METHODS Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling. Changes in SAT and VAT levels (determined by abdominal MRI), insulin sensitivity (according to the Matsuda index), and β-cell function (β-index) were assessed during a multiple-sampling oral glucose tolerance test; and circulating levels of IGF-I and IGF-II were assessed before and after a comparable weight loss (7% of initial body weight). RESULTS After comparable weight loss, achieved by 20 patients per arm, and superimposable glycemic control, as reflected by HbA1c level (P = 0.60), reduction in VAT was significantly higher in the liraglutide arm than in the lifestyle arm (P = 0.028), in parallel with a greater improvement in β-index (P = 0.021). No differences were observed in SAT reduction (P = 0.64). IGF-II serum levels were significantly increased (P = 0.024) only with liraglutide administration, and the increase in IGF-II levels correlated with both a decrease in VAT (ρ = −0.435, P = 0.056) and an increase in the β-index (ρ = 0.55, P = 0.012). CONCLUSIONS Liraglutide effects on visceral obesity and β-cell function might provide a rationale for using this molecule in obese subjects in an early phase of glucose metabolism dysregulation natural history. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|